SCHEMBL12401679

SCHEMBL12401679

CCCC(NC(C)(C)C)C(=O)C(=O)NCCc1c[nH]c2ccc(C(C)=O)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
MTNR1A P48039 7/20 0.46
MTNR1B P49286 6/20 0.46
NOTUM Q6P988 3/20 0.46
CYP1A2 P05177 3/20 0.46
SPR P35270 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
HPGD P15428 2/20 0.46
BLM P54132 2/20 0.46
MAPT P10636 2/20 0.46
IDO1 P14902 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NQO2 P16083 3/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16328220 0.89 HTR1A (0.53) HTR1AHTR1DHTR1BMTNR1AMTNR1B
SCHEMBL12401699 0.89 MTNR1A (0.58) MTNR1AMTNR1BNOTUMCYP1A2SPR
SCHEMBL12404686 0.86 MTNR1A (0.63) HTR1AMTNR1AMTNR1BNOTUMCYP1A2
SCHEMBL12404682 0.84 HTR1A (0.44) HTR1AHTR1DHTR1BCYP1A2KDM4E
SCHEMBL12401667 0.83 MTNR1A (0.47) MTNR1AMTNR1BMAPTKMT2APOLB
SCHEMBL15338726 0.77 SPR (0.62) NOTUMCYP1A2SPRKDM4EALDH1A1
SCHEMBL19229515 0.77 MTNR1A (0.74) HTR1AHTR1DHTR1BMTNR1AMTNR1B
SCHEMBL14943234 0.75 MTNR1A (0.66) HTR1AMTNR1AMTNR1BNOTUMCYP1A2
SCHEMBL12468420 0.74 MTNR1A (0.65) HTR1AMTNR1AMTNR1BNOTUMCYP1A2
SCHEMBL14943212 0.73 HTR1A (0.47) HTR1AHTR1DHTR1BCYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 HTR1A 2480/4885HTR1D 2934/4885HTR1B 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.